21-237 Lineberger Comprehensive Cancer Center
Campus Box 7295
Chapel Hill, NC 27599-7295
Dr. McKinnon isolates and expands human dendritic cells for DC-based vaccines in breast cancer clinical trials of the Lineberger Comprehensive Cancer Center. Dr. McKinnon develops and validates assays that monitor tumor specific immune responses following DC-based vaccines. Dr. McKinnon prepares and maintains the Standard Operating Procotols required by the FDA that support several DC based clinical trials.
Kurtz S, McKinnon KP, Runge MS, Ting JP, Braunstein M (2006). The SecA2 secretion factor of Mycobacterium tuberculosis promotes growth in macrophages and inhibits the host immune response. Infect Immun. 74(12):6855-64.
Eun SY, O'Connor BP, Wong AW, van Deventer HW, Taxman DJ, Reed W, Li P, Blum JS, McKinnon KP, Ting JP (2006). Cutting edge: rho activation and actin polarization are dependent on plexin-A1 in dendritic cells. J Immunol. 177(7):4271-5.
Moran, T.P., M. Collier, K.P. McKinnon, N.L. Davis, R.E. Johnston, J.S. Serody. A novel viral system for generating antigen-specific T cells. J Immunol. 2005 Sep 1;175(5):3431-8.
Charlermskulrat W., K. McKinnon, W.J, Brickey, I. Neuringer, R.C. Park, D.G. Sterka, B. Long, P. McNeillie, R. Noelle, J.P. Ting, R.M. Aris. Combined donor-specific transfusion and anti-CD154 therapy achieves airway allograft tolerance. Thorax. 2005 Oct 27